Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer.
Otoya I, Valdiviezo N, Morante Z, Calle C, Ferreyra Y, Huarcaya-Chombo N, Polo-Mendoza G, Castañeda C, Vidaurre T, Neciosup SP, Calderón MJ, Gomez HL. Otoya I, et al. Among authors: valdiviezo n. Int J Breast Cancer. 2024 Jun 22;2024:9551710. doi: 10.1155/2024/9551710. eCollection 2024. Int J Breast Cancer. 2024. PMID: 38962673 Free PMC article.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Lung Cancer in Peru.
Ruiz R, Galvez-Nino M, Poquioma E, Limache-García A, Amorin E, Olivera M, Valdiviezo N, Trejo JM, Heredia A, Sarria G, Aguilar A, Raez L, Neciosup SP, Gomez HL, Payet E, Mas L. Ruiz R, et al. Among authors: valdiviezo n. J Thorac Oncol. 2020 Jun;15(6):891-898. doi: 10.1016/j.jtho.2020.01.018. J Thorac Oncol. 2020. PMID: 32471564 Free article. No abstract available.
Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study.
Valdiviezo N, Alcarraz C, Castro D, Salas R, Begazo-Mollo V, Galvez-Villanueva M, Medina Aguirre L, Garcia-León E, Quispe-Santivañez I, Cornejo-Raymundo C, Paz-Cornejo E, Sanchez-Vilela L, Bermudez-Alfaro V, Vargas-Nina JC, Pérez-Ramos C, Meza-Hoces A, Valdez Barreto PR, Huaringa-Leiva R, Muro-Cieza J, Aguilar-Vásquez V, Cuenca EY, Neciosup-Delgado S, Poma-Nieto N, Chavez-Gavino S, Fernandez-Rosas L, Araujo JM, Payet E, Gomez HL. Valdiviezo N, et al. Cancer Manag Res. 2022 Mar 8;14:1075-1085. doi: 10.2147/CMAR.S350038. eCollection 2022. Cancer Manag Res. 2022. PMID: 35300062 Free PMC article.
Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis.
Galvez-Nino M, Roque K, Ruiz R, Namuche F, Paitan V, Arrese T, Zegarra J, Oblitas G, Gonzalez L, Maco L, Cabrera MDP, Coello R, Portugal Del Pino JL, Ezquerra JC, Perez Roca R, Coanqui O, Valdiviezo N, Olivera M, Vidaurre T, Aguilar Cartagena A, Mas L. Galvez-Nino M, et al. Among authors: valdiviezo n. Cancer Treat Res Commun. 2025;43:100906. doi: 10.1016/j.ctarc.2025.100906. Epub 2025 Mar 22. Cancer Treat Res Commun. 2025. PMID: 40147101 Free article.
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.
Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ, Leiva M, Cetina-Pérez LDC, Varga S, Molina Alavez A, Alarcon-Rozas AE, Valdiviezo N, Acevedo C, Figueroa A, Santini A, Vera L, Rey F, Kahán Z, Galaz P, Meléndez Mier G, Wu X, Mandai M, Shapira-Frommer R, Estevez-Diz MDP, Limaye S, Xin W, Dry H, Broggi MAS, Yuan DY, Stewart RA, Monk BJ. Mayadev J, et al. Among authors: valdiviezo n. Ann Oncol. 2025 Jun 2:S0923-7534(25)00738-0. doi: 10.1016/j.annonc.2025.05.533. Online ahead of print. Ann Oncol. 2025. PMID: 40500687 Free article.
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Lu S, et al. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828946 Clinical Trial.
A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.
Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Geater SL, Maurel JM, Rojas C, Takahashi T, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Ahmed Chaudhry A, Yang JC. Jänne PA, et al. Among authors: valdiviezo n. Future Oncol. 2025 Apr;21(8):917-928. doi: 10.1080/14796694.2025.2463318. Epub 2025 Mar 6. Future Oncol. 2025. PMID: 40051276 Free PMC article.
30 results